Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 4

Arterial Stiffness and Pharmacological Interventions – The TRanscend Arterial stiffNess Substudy (TRANS study)

Authors Jirar Topouchian, Ramzi El Feghali, Bruno Pannier, Shuyu Wang, Feng Zhao, Karel Smetana, Koon Teo, Roland Asmar

Published 15 September 2007 Volume 2007:3(4) Pages 381—388

Jirar Topouchian1, Ramzi El Feghali1, Bruno Pannier1, Shuyu Wang2, Feng Zhao3, Karel Smetana4, Koon Teo3, Roland Asmar1

1The CardioVascular Institute, Paris, France; 2Beijing Clinical Trial and Research Center, Beijing, China; 3Population Health Research Institute, Hamilton, Canada; 4Vojenska nemocnice Plzen, Pizen, Czech Republic

Abstract: The degree of arterial stiffness is correlated with the risk of cardiovascular diseases and it is a powerful predictor for morbidity and mortality. Studies have shown that arterial stiffness reduction is associated with an improvement in survival. Reduction of arterial stiffness by pharmacological drugs varies according to the drugs and doses used and duration of treatment. This effect on the arteries differs among the various classes of drugs and among individual drugs in the same class. Quantification of the stiffness and other properties of the arterial wall can be used to monitor the responses to therapy in individuals with hypertension and other cardiovascular diseases. These measures can then be used as surrogate markers for the risk of clinical events. Inhibition of the renin-angiotensin system (RAS) is associated with an important decrease in cardiovascular risk. Findings from clinical trials support the hypothesis that the protective effects of RAS inhibition are partly independent from blood pressure reduction and related to several mechanisms including vascular protective effects. The aim of the TRanscend Arterial stiffNess Substudy (TRANS) is to assess the effect of an angiotensin II receptor blocker (ARB), telmisartan, on the arterial stiffness in a subgroup of patients from the Telmisartan Randomized Assessment Study in aCE iNtolerant subjects with cardiovascular Disease (TRANSCEND) trial. The TRANSCEND trial is an international, multicenter, randomized double blind placebo controlled trial of telmisartan that enrolled patients at high risk for cardiovascular events. Some clinical baseline data of the TRANS substudy are reported. When completed, the results of the TRANS substudy will show whether the beneficial effects of treatment with telmisartan on cardiovascular outcome may be related to an improvement in arterial stiffness.

Keywords: arterial stiffness, cardiovascular prevention, ARBs, telmisartan, pulse wave velocity, antihypertensive

Download Article [PDF] 

Readers of this article also read:

Assessment of antitumor activity and acute peripheral neuropathy of 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016)

Ueno T, Endo K, Hori K, Ozaki N, Tsuji A, Kondo S, Wakisaka N, Murono S, Kataoka K, Kato Y, Yoshizaki T

International Journal of Nanomedicine 2014, 9:3005-3012

Published Date: 19 June 2014

Evaluation of tensile strength of tissue adhesives and sutures for clear corneal incisions using porcine and bovine eyes, with a novel standardized testing platform

Kaja S, Goad DL, Ali F, Abraham A, Rebenitsch RL, Teymoorian S, Krishna R, Koulen P

Clinical Ophthalmology 2012, 6:305-309

Published Date: 28 February 2012

Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update

Juan V Llau, Raquel Ferrandis, Pilar Sierra, et al

Vascular Health and Risk Management 2010, 6:855-867

Published Date: 29 September 2010

Health literacy and health seeking behavior among older men in a middle-income nation

Paul A Bourne, Chloe Morris, Christopher AD Charles, et al

Patient Related Outcome Measures 2010, 1:39-49

Published Date: 26 May 2010

Blood pressure reduction due to hemoglobin glycosylation in type 2 diabetic patients

Pedro Cabrales, Miguel A Salazar Vázquez, Beatriz Y Salazar Vázquez, Martha Rodríguez-Morán, Marcos Intaglietta, Fernando Guerrero-Romero

Vascular Health and Risk Management 2008, 4:917-922

Published Date: 8 August 2008

A review of nateglinide in the management of patients with type 2 diabetes

Nicholas Tentolouris, Christina Voulgari, Nicholas Katsilambros

Vascular Health and Risk Management 2007, 3:797-807

Published Date: 15 January 2008

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications

Behzad Molavi, Negah Rassouli, Suveer Bagwe, Neda Rasouli

Vascular Health and Risk Management 2007, 3:967-973

Published Date: 15 January 2008

Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes

John Pullman, Tamara Darsow, Juan P Frias

Vascular Health and Risk Management 2006, 2:203-212

Published Date: 15 September 2006